To debate the utility and appropriateness of real-world evidence against clinical trials for treating patients with hematologic malignancies, Chadi welcomes back Aaron Goodman, MD, hematologist, University of California San Diego, and Alan Skarbnik, MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), as well as invites first-time guest Liz Brem, MD, assistant clinical professor of hematology, UC Irvine. Can RCT designers ever escape inherent bias? Will we ever enroll a more diverse, higher volume patient population in clinical trials? Who has the right to criticize a clinical trial design? The group uses a phase I study published in Lancet Hematology to frame their arguments in this riveting, hotly contested discussion.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
